Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283373 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01283373 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 84 participants.
The verdict
NCT01283373, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
Interventions
- DRUG DSTP3086S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283373
The ClinicalTrials.gov registry entry for NCT01283373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DSTP3086S is the first listed.
NCT01283373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283373 about?
NCT01283373 is a clinical study titled "A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer". This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
What is the current status of trial NCT01283373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2011-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01283373?
The interventions under investigation include: DSTP3086S (DRUG).
Who is sponsoring clinical trial NCT01283373?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.